ClinicalTrials.gg
CompletedNCT06299111ROXI-CATHUpdated Apr 13, 2026

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

A Phase 2 interventional study of REGN9933 and REGN7508 in Venous Thromboembolism, sponsored by Regeneron Pharmaceuticals. Completed at 23 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies in Venous Thromboembolism with a site in Israel — 3 open to participants now, 3 under way, none of them phase 3. Venous Thromboembolism · Israel.

Enrollment
24th of 28
195 · median 845
Started
2024
the only one that year
Phase 2
7 of 33
none open now
Registered
31st of 33
by date

Among the 33 studies in Venous Thromboembolism with a site in Israel, this one is the 24th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2024, is one of 7 in phase 2, and was the 31st registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

3 of the 33 studies in Venous Thromboembolism with a site in Israel are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Venous Thromboembolism with a site in Israel, or all of them as a file.
02

Study summary

This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'.

The aim of the study is to see how effective the study drug is at preventing venous thromboembolism (VTE) and other related disease after catheter placement.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
03

Conditions studied

  • Venous Thromboembolism

Keywords

  • Anti-factor XI (FXI) monoclonal antibody
  • Venous Thromboembolism
  • Peripherally inserted central catheter
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. PICC is clinically indicated for at least 14 days and is anticipated to remain in place for at least 14 days
  2. (ECOG) Performance Status ≤2 or equivalent functional status as described in the protocol
  3. Body weight ≥45 kg and ≤130 kg during the screening period
  4. (INR) and aPTT values at or below the as defined by the local lab during the screening period
  5. count ≥100 x 10\^9/L during the screening period as described in the protocol

Key Exclusion Criteria:

  1. Unsuccessful PICC placement or any other complication associated with this procedure that in the opinion of the study investigator may present any safety concerns to the participant
  2. History of prior venous thrombosis in the arm in which the PICC is to be placed
  3. Peripheral catheter(s) in the same arm in which the PICC is to be placed or expected need for peripheral catheter(s) placement in the same arm the PICC is to be placed as described in the protocol
  4. History of known thromboembolic disease or thrombophilia
  5. Participants requiring therapeutic anticoagulation and/or antiplatelet therapy as described in the protocol
  6. Expected to receive cancer therapy or other medication associated with a prior episode of Grade 4 thrombocytopenia as described in the protocol
  7. Any history of intracranial or intraocular bleeding, excessive operative or post-operative bleeding, traumatic spinal or epidural anesthesia, or history of bleeding diathesis (such as but not limited to Hemophilia A or B, von Willebrand's disease, fibrinogen deficiency, and other inherited or acquired bleeding disorders) as described in the protocol

Note: Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
195 participants (actual)

Study arms

  • Experimental
    REGN9933

    Randomized 1:1:1

    Drug: REGN9933

  • Experimental
    REGN7508

    Randomized 1:1:1

    Drug: REGN7508

  • Placebo comparator
    Placebo

    Randomized 1:1:1

    Drug: Placebo

Interventions

  • Intravenous (IV) single dose administered

  • IV single dose administered

  • DrugPlacebo

    IV single dose administered

06

What researchers measure

Primary outcomes

  1. Incidence of confirmed VTE per central reading center (CRC) review

    Time frame: Through Day 14

  2. Incidence of treatment-emergent adverse event (TEAEs)

    Time frame: Up to Day 100

  3. Severity of TEAEs

    Time frame: Up to Day 100

Secondary outcomes

  1. Incidence of confirmed PICC associated venous thrombosis per CRC review

    Time frame: Through Day 14

  2. Incidence of major bleeding

    Time frame: Through Day 14

  3. Incidence of clinically relevant non-major (CRNM) bleeding

    Time frame: Through Day 14

  4. Concentrations of REGN9933 in serum

    Time frame: Up to Day 75

  5. Concentrations of REGN7508 in serum

    Time frame: Up to Day 75

  6. Change in activated partial thromboplastin time (aPTT)

    Time frame: Up to Day 75

  7. Change in prothrombin time (PT)

    Time frame: Up to Day 75

  8. Incidence of anti-drug antibody (ADA) to REGN9933 over time

    Time frame: Up to Day 75

  9. Magnitude of ADA to REGN9933 over time

    Time frame: Up to Day 75

  10. Incidence of ADA to REGN7508 over time

    Time frame: Up to Day 75

  11. Magnitude of ADA to REGN7508 over time

    Time frame: Up to Day 75

07

Study locations

23 sites
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Memorial Sloan Kettering
    New York, New York 10065, United States
  • Sveta Sofia Hospital
    Sofia, 1000, Bulgaria
  • Juravinski Hospital
    Hamilton, Ontario L8V 1C3, Canada
  • London Health Sciences Centre
    London, Ontario N6A 4L6, Canada
  • Lakeridge Health
    Oshawa, Ontario L1G 2B9, Canada
  • University Health Network
    Toronto, Ontario M5G 2M9, Canada
  • Shaare Zedek Medical Center
    Jerusalem, Jerusalem 9103102, Israel
  • Soroka University Medical Center
    Beersheba, Southern District 84101, Israel
  • Hadassah University Medical Center
    Jerusalem, 91120, Israel
  • Lanadio Medical Center
    Netanya, 4244916, Israel
  • Rabin Medical Center
    Petah Tikva, 49100, Israel
  • Sheba Medical Center
    Ramat Gan, 5265601, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Arensia Research Clinic
    Bucharest, 011658, Romania
  • Arensia Exploratory Medicine Clinic at Country Hospital Cluj-Napoca
    Cluj-Napoca, 400006, Romania
  • University hospital Southampton
    Southampton, Hampshire SO16 6YD, United Kingdom
  • Cardiff and Vale University Health Board - University Hospital Wales
    Cardiff, Wales CF14 4XW, United Kingdom
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Newcastle upon Tyne, NE1 4LP, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Mar 2026, 18 months.

Of 27 phase 2 interventional studies under Venous Thromboembolism, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 7, 2024
StartActual
Sep 20, 2024
Primary completionActual
Mar 27, 2026
CompletionActual
Mar 27, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06299111
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
Sep 20, 2024
Primary completion
Mar 27, 2026
Completion
Mar 27, 2026
Last update
Apr 13, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amrecibart · Cenvacibart

Start the discussion